OBJECTIVES: The authors previously reported that repetitive transcranial magnetic stimulation (rTMS) produced a response rate of 39.4% among 62 patients with treatment resistant vascular depression. This study was undertaken to assess the outcome of continuation therapy to prevent relapse among these patients during 9 weeks after completion of rTMS. DESIGN: Patients were randomly assigned to 18,000 pulses of rTMS given over 3 weeks or sham treatment using double blind methods. After rTMS, all patients were given 20 mg/day of citalopram for 9 weeks and reevaluated at 3, 6, and 9 weeks. SETTING: Outpatient continuation treatment trial. PARTICIPANTS: Patients with vascular depression (N = 62), as determined by magnetic resonance imaging hyperintensities and three or more clinical risk factors for vascular disease without other major medical illness, were recruited. They had onset of major depression after age 50 and failed at least one trial of antidepressants. INTERVENTION: After rTMS or sham treatment, all treatment responders were given citalopram for 9 weeks. RESULTS: Among the 33 patients who were givenrTMS, 13 responded (i.e., >50% decline in Hamilton Depression Scale score). Of these 13, all completed the 9 weeks of continuation treatment. There were nine patients who continued to be responders and four who had a relapse of depression. CONCLUSION: More effective methods are needed to treat elderly patients with treatment resistant vascular depression and to prevent relapse among treatment responders.
RCT Entities:
OBJECTIVES: The authors previously reported that repetitive transcranial magnetic stimulation (rTMS) produced a response rate of 39.4% among 62 patients with treatment resistant vascular depression. This study was undertaken to assess the outcome of continuation therapy to prevent relapse among these patients during 9 weeks after completion of rTMS. DESIGN:Patients were randomly assigned to 18,000 pulses of rTMS given over 3 weeks or sham treatment using double blind methods. After rTMS, all patients were given 20 mg/day of citalopram for 9 weeks and reevaluated at 3, 6, and 9 weeks. SETTING:Outpatient continuation treatment trial. PARTICIPANTS: Patients with vascular depression (N = 62), as determined by magnetic resonance imaging hyperintensities and three or more clinical risk factors for vascular disease without other major medical illness, were recruited. They had onset of major depression after age 50 and failed at least one trial of antidepressants. INTERVENTION: After rTMS or sham treatment, all treatment responders were given citalopram for 9 weeks. RESULTS: Among the 33 patients who were given rTMS, 13 responded (i.e., >50% decline in Hamilton Depression Scale score). Of these 13, all completed the 9 weeks of continuation treatment. There were nine patients who continued to be responders and four who had a relapse of depression. CONCLUSION: More effective methods are needed to treat elderly patients with treatment resistant vascular depression and to prevent relapse among treatment responders.
Authors: V A Magnotta; N C Andreasen; S K Schultz; G Harris; T Cizadlo; D Heckel; P Nopoulos; M Flaum Journal: Cereb Cortex Date: 1999-03 Impact factor: 5.357
Authors: M D Miller; C F Paradis; P R Houck; S Mazumdar; J A Stack; A H Rifai; B Mulsant; C F Reynolds Journal: Psychiatry Res Date: 1992-03 Impact factor: 3.222
Authors: Charles H Kellner; Rebecca G Knapp; Georgios Petrides; Teresa A Rummans; Mustafa M Husain; Keith Rasmussen; Martina Mueller; Hilary J Bernstein; Kevin O'Connor; Glenn Smith; Melanie Biggs; Samuel H Bailine; Chitra Malur; Eunsil Yim; Shawn McClintock; Shirlene Sampson; Max Fink Journal: Arch Gen Psychiatry Date: 2006-12
Authors: N C Andreasen; R Rajarethinam; T Cizadlo; S Arndt; V W Swayze; L A Flashman; D S O'Leary; J C Ehrhardt; W T Yuh Journal: J Comput Assist Tomogr Date: 1996 Jan-Feb Impact factor: 1.826
Authors: H A Sackeim; R F Haskett; B H Mulsant; M E Thase; J J Mann; H M Pettinati; R M Greenberg; R R Crowe; T B Cooper; J Prudic Journal: JAMA Date: 2001-03-14 Impact factor: 56.272
Authors: Charles F Reynolds; Mary Amanda Dew; Bruce G Pollock; Benoit H Mulsant; Ellen Frank; Mark D Miller; Patricia R Houck; Sati Mazumdar; Meryl A Butters; Jacqueline A Stack; Mary Ann Schlernitzauer; Ellen M Whyte; Ariel Gildengers; Jordan Karp; Eric Lenze; Katalin Szanto; Salem Bensasi; David J Kupfer Journal: N Engl J Med Date: 2006-03-16 Impact factor: 91.245
Authors: Mariagiovanna Cantone; Giuseppe Lanza; Francesco Fisicaro; Manuela Pennisi; Rita Bella; Vincenzo Di Lazzaro; Giovanni Di Pino Journal: Neural Plast Date: 2020-10-27 Impact factor: 3.599